Huahai Pharmaceutical wins key valsartan litigation case

Zhejiang Huahai Pharmaceutical Co., Ltd. recently announced that the U.S. District Court for the District of New Jersey ruled in its favor in the "Gaston Roberts" personal injury lawsuit, dismissing all claims by the plaintiff. This case was chosen as the first bellwether case among numerous valsartan-related lawsuits filed against the company and its subsidiaries, including Prinston Pharmaceutical Inc. and SciHealth US Inc.

The plaintiff in the "Gaston Roberts" case has 30 days from receiving the verdict to decide whether to appeal. The company stated it cannot currently assess the financial impact of this litigation, as the ultimate outcome depends on subsequent case developments, effective court judgments, and enforcement results.

The lawsuits stem from allegations by U.S. consumers that trace amounts of NDMA (N-Nitrosodimethylamine) were found in valsartan active pharmaceutical ingredient. While the "Gaston Roberts" ruling is specific to this case, the company has engaged legal counsel to address all related litigation.